Skin Effector Memory T Cells Do Not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL Patients

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

1999 • 5,659 citations

WHO-EORTC classification for cutaneous lymphomas

2005 • 3,617 citations

Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance

2004 • 2,910 citations

Reshaping human antibodies for therapy

1988 • 1,555 citations

Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus

2009 • 1,038 citations

Naive and memory T cells show distinct pathways of lymphocyte recirculation.

1990 • 792 citations

The Vast Majority of CLA+ T Cells Are Resident in Normal Skin

2006 • 741 citations

Long-term Outcome of 525 Patients With Mycosis Fungoides and Sézary Syndrome

2003 • 632 citations

The window of therapeutic opportunity in multiple sclerosis

2005 • 497 citations

Sézary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors

2010 • 472 citations

Kidney Cancer

2009 • 463 citations

Migration, maintenance and recall of memory T cells in peripheral tissues

2009 • 405 citations

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome

2003 • 390 citations

Non-Hodgkin’s Lymphomas

2010 • 337 citations

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model

2009 • 319 citations

Humanised monoclonal antibody therapy for rheumatoid arthritis

1992 • 316 citations

Skin-Resident T Cells: The Ups and Downs of On Site Immunity

2009 • 274 citations

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.

1998 • 264 citations

Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders

2006 • 263 citations

Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell–mediated immunity

2010 • 232 citations

Oncogenomic analysis of mycosis fungoides reveals major differences with Sézary syndrome

2008 • 207 citations

Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma

2007 • 207 citations

A Novel Method for the Isolation of Skin Resident T Cells from Normal and Diseased Human Skin

2006 • 183 citations

Sezary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain)

1996 • 172 citations

Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients

2007 • 168 citations

Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab

2003 • 143 citations

Phase II study of alemtuzumab in chronic lymphoproliferative disorders

2003 • 128 citations

Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome

2004 • 127 citations

Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome

2007 • 126 citations

Lymphocyte apoptosis during the silencing of the immune response to acute viral infections in normal, lpr, and Bcl-2-transgenic mice.

1995 • 116 citations

The Immunopemthogenesis of Cutaneous T-cell Lymphoma

1995 • 108 citations

Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center

2009 • 102 citations

Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma

2010 • 98 citations

Treatment of Stage IA Cutaneous T-Cell Lymphoma With Topical Application of the Immune Response Modifier Imiquimod

2002 • 94 citations

Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity

2001 • 83 citations

Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models

2010 • 75 citations

High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma

2010 • 60 citations

A Human CD4 Monoclonal Antibody for the Treatment of T-Cell Lymphoma Combines Inhibition of T-Cell Signaling by a Dual Mechanism with Potent Fc-Dependent Effector Activity

2007 • 51 citations

Abnormal cytokine expression in Sézary and adult T-cell leukemia cells correlates with the functional diversity between these T-cell malignancies.

1994 • 44 citations

Subcutaneous alemtuzumab for Sézary Syndrome in the very elderly

2007 • 38 citations

Successful treatment of chemotherapy‐refractory Sézary syndrome with alemtuzumab (Campath‐1H)

2003 • 36 citations

Spotlight on alemtuzumab.

2009 • 32 citations

Monitoring the Decrease of Circulating Malignant T Cells in Cutaneous T-Cell Lymphoma During Photopheresis and Interferon Therapy

2003 • 31 citations

Mycosis Fungoides/Sézary Syndrome: A Report of Three Cases Treated with Campath-1H as Salvage Treatment

2003 • 18 citations

Fatal adenoviral and enteroviral infections and an Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory Sézary syndrome

2008 • 17 citations

Alemtuzumab: effective monotherapy for simultaneous B‐cell chronic lymphocytic leukaemia and Sézary syndrome

2004 • 14 citations

Principles of Cytotoxic T Lymphocyte Induction and Recognition

1995 • 11 citations

Alemtuzumab in Sézary syndrome: efficient but not innocent.

2007 • 11 citations

Measuring Humanized Antibodies in Plasma of Patients Treated With Antibody-Based Therapy Using Bead-Based Flow Cytometry

2007 • 3 citations